Field Name	Field Description
Prior Authorization Group Description	Hydroxyprogesterone caproate (generic Delalutin)
Drugs	Hydroxyprogesterone caproate (generic Delalutin)
Covered Uses	Medically accepted indications are defined using the following
	sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Pregnancy
Required Medical Information	See "Other Criteria"
Age Restrictions	According to package insert
Prescriber	Prescriber must be a gynecologist or in consultation with a
<u>Restrictions</u>	gynecologist
Coverage	If all the criteria are met, the initial request will be approved for up
<u>Duration</u>	to 6 months. For continuation of therapy, the request will be approved for up to 6 months.
Other Criteria	**Drug is being requested through the member's medical benefit**
	Initial Authorization:
	Medication is prescribed at an FDA approved dose
	• If request is for preterm birth, do not approve
	• Request is for one of the following indications:
	o Amenorrhea or abnormal uterine bleeding due to
	<u>hormonal imbalance</u>
	o <u>Production of secretory endometrium and desquamation</u>
	o <u>Test for endogenous estrogen production</u>
	o Advanced uterine adenocarcinoma
	Re-Authorization:
	Documentation or provider attestation of clinical benefit
Revision/Review Date: 4/2024	Medication is prescribed at an FDA approved dose
	If all the above criteria are not met, the request is referred to a
	Medical Director/Clinical Reviewer for medical necessity review.